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The impact of changing NRT licensing laws in the UK: findings 
from the International Tobacco Control Four Country Survey. 
Lion Shahab, K. Michael Cummings, David Hammond, Ron Borland, Robert 
West, Ann McNeill 
ABSTRACT 
Aim: To evaluate the impact of a new licence for some nicotine replacement therapy 
products (NRT) for cutting down to stop (CDTS), on changes in the pattern of NRT 
use. 
Design: Quasi-experimental design comparing changes in NRT use across two 
waves of a population-based, replenished-panel, telephone survey conducted before 
and after the introduction of new licensing laws in the UK with changes in NRT use in 
three comparison countries (Australia, Canada and United States) without a licensing 
change. 
Participants: 7386 and 7013 smokers and recent ex-smokers participating in the 
2004 and/or 2006/7 survey. 
Measurements: Data were collected on demographic and smoking characteristics as 
well as NRT use and access. In order to account for interdependence resulting from 
some participants being present in both waves, generalised estimation equations with 
an exchangeable correlation matrix were used to assess within-country changes and 
linear and logistic regressions to assess between-country differences in adjusted 
analyses. 
Findings: NRT use was more prevalent in the UK and increased across waves in 
both all countries but no wave by country interaction was observed. There was no 
evidence that the licensing change increased the prevalence of CDTS or the use of 
NRT (irrespective of how it was accessed) for CDTS in the UK relative to comparison 
countries. There was also no evidence for a change in concurrent smoking and NRT 
use among smokers not attempting to stop in the UK relative to comparison countries. 
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Conclusion: The addition of the CDTS licence for some NRT products in the UK 
appears to have had very limited, if any, impact on NRT use in the first year after the 
licence change. 
 
Key words: Nicotine replacement therapy, Smoking cessation, Tobacco use, 
Reduce-to-quit 
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INTRODUCTION 
Nicotine Replacement Therapy (NRT) is an effective smoking cessation treatment 
and is currently available in six different forms in the UK (patch, gum, lozenge, 
microtab, inhalator or nasal spray), each providing nicotine variously through the skin, 
the oral or the nasal mucosal membrane.[1] NRT reduces withdrawal symptoms and 
urges to smoke [2] and has been shown to roughly double a smoker’s chances of 
quitting successfully.[3] NRT is effective even with minimal behavioural support and 
supervision. [4] 
 
In the UK, NRT can be purchased over the counter (OTC) from pharmacies and, with 
the classification of some NRT products in the general sale category, in supermarkets 
and at other outlets.[5] NRT also became available subsidised on prescription in the 
UK in 2001, which allowed smokers to purchase NRT at a reduced or no cost 
depending on income level.[6] In September 2005, changes in the licensing for NRT 
reduced the number of cautions and contra-indications for NRT and thus permit its 
use by pregnant smokers, adolescent smokers or smokers with heart disease. These 
changes were implemented as it was felt that the potential risks of NRT use among 
these smokers were much less than the risks associated with continued smoking.[7] 
 
Another change to NRT licensing laws that came into effect in 2005 was to permit 
smokers to use two NRT products, namely nicorette gum and nicorette inhaler, to cut 
down the number of cigarettes smoked prior to attempting to stop smoking completely 
over a six month period, and with a view to stopping NRT use within a 12 month 
period. The change in regulation was informed by an increasing evidence base 
suggesting that smokers who use NRT to gradually reduce their cigarette 
consumption are more likely to stop smoking than smokers who try to cut down using 
a placebo.[8-11] The use of these NRT products for gradual cessation was advertised 
on TV (although the advertisement showed a smoker using NRT at work perhaps 
Impact of NRT licensing change 
 6 
therefore being more illustrative of use in situations of temporary abstinence) and was 
also indicated on the packaging. While the licensing change was applied irrespective 
of how NRT was accessed, it was suggested that the UK smoking cessation services 
should only get involved once the smoker attempted to stop smoking completely [7]. 
Hence NRT prescribed by the services (or indeed other prescribers) would have been 
more likely to have been given for quitting rather than cutting down. Any changes in 
NRT used for cutting down to stop (CDTS) are likely to have been most pronounced 
among users of NRT who obtained it OTC. 
 
It has been previously reported that changes in licensing can lead to an increase in 
the use of NRT[12]. This study evaluates the effect of a new indication for NRT 
products to allow their use for cutting down prior to attempting to stop completely. Our 
analysis is based upon data from the International Tobacco Control (ITC) Four 
Country Survey collected before and after the introduction of the new licensing laws in 
the UK. For comparison purposes we also examine data on NRT usage patterns from 
three countries (Australia, Canada and USA) where no commensurate change in 
NRT labelling and usage rules occurred. We hypothesize that the UK licensing will 
have led to:  
1.) An increase in the use of NRT, in particular NRT obtained OTC, in the UK relative 
to comparison countries. 
2.) An increase in the incidence of smokers attempting to stop smoking gradually in 
the UK relative to comparison countries. 
3.) An increase in the incidence of smokers attempting to stop smoking gradually with 
NRT, especially NRT obtained OTC, in the UK relative to comparison countries. 
 
We also hypothesise that a potential side-effect of the policy change may be that: 
4.) Smokers not attempting to stop may be more likely to concurrently use NRT in the 
UK relative to comparison countries and that therefore fewer smokers attempt to quit. 
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METHODS 
Participants and study design 
The ITC Four Country Survey is a yearly cohort survey that includes a representative 
sample of adult smokers and ex-smokers from Australia (AU), Canada (CA), the 
United Kingdom (UK) and the United States (US). Since 2002, six surveys have been 
carried out. The ITC survey assesses the impact of national-level tobacco control 
policies on psychosocial, behavioural and attitudinal correlates of tobacco use. The 
methodology has been described in detail elsewhere.[13] Briefly, participants were 
recruited by phone with a probability sampling method; eligible households, stratified 
by geographic region and community size, were randomly selected using random-
digit dialling methods. Only individuals who were 18 years or older, had smoked more 
than 100 cigarettes in their life and at least once in the past month were included. 
Participants were reimbursed the equivalent of US$10 for their time at each wave. In 
the five follow-up surveys, the recruited sample has been replenished to ensure a 
sufficient sample size (2000 per country). Ethical approval was provided by 
participating research institutes in the four countries. Full details of the sampling 
design and procedure can be found at http://www.itcproject.org. 
 
A quasi-experimental design was chosen for this analysis, comparing changes in 
NRT use across two waves in the UK relative to comparison countries where no 
changes in NRT licensing had occurred. We identified participants who completed 
either wave 3, which was carried out before the UK licensing change (June - Dec 
2004), and/or wave 5, conducted after the UK licensing change (Oct 2006 - Feb 
2007). For the purpose of this analysis, participants had to be daily smokers at 
recruitment or recent ex-smokers (stopped < 6 months ago). A total of 7386 and 7013 
adults fitting these inclusion criteria participated in waves 3 and 5 respectively, of 
whom 3307 (44.8% of wave 3 and 47.2% of wave 5) participated in both waves. As 
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waves 3 and 5 of this cohort study were treated as cross-sectional surveys, within-
subject interdependence was modeled in the statistical analysis (see Analyses). 
Table 1 provides sample characteristics for each wave. 
 
Measures 
Survey questions were standardised across countries and waves but wording was 
adapted where necessary to account for colloquial differences. Phone interviews 
followed a strict protocol using Computer Assisted Telephone Interviewing software to 
minimise bias and increase reliability. 
 
Demographics  
Age, sex, ethnicity (2 categories; “white/English-speaking at home”, ”non-white/non 
English-speaking at home”), education level (3 categories; “low/secondary school or 
less”, “moderate/some postsecondary training”, “high/postsecondary degree or 
higher”) and annual income (3 categories: “low/under equivalent of US$30,000“, 
“moderate/US$30,000-59,999”, and “high/US$60,000 and over”) were all assessed at 
recruitment and monitored for changes across waves. 
 
Smoking Characteristics 
Smoking status was determined by self-report through a series of questions 
assessing current and past smoking behaviour. Respondents were categorised as 
current smokers and ex-smokers (quit less than 1 month, 1-6 months or more than 6 
months ago). Current smokers were asked about their intention to quit (Yes/No). 
Nicotine dependence was assessed with the heaviness-of-smoking index (HSI) which 
produces a range of values (0-6) that are based on summative categories of the time 
to first cigarette and the number of cigarettes per day.[14] 
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Participants were asked about their quitting behaviour, either in the past year if they 
were newly recruited, or since the last survey (roughly a year ago) if there were 
followed up. Those who had attempted to quit at least once in this time-frame 
(referred to here as ‘quit attempters’) were asked whether, on their most recent quit 
attempt, they had stopped smoking gradually or suddenly and whether they had used 
any cessation aids to do so. Irrespective of NRT use, participants who indicated that 
they had attempted to stop smoking and had done so by gradually reducing their 
consumption were defined as using ‘cut-down-to-stop’ (CDTS). 
 
NRT Use 
Irrespective of quit attempts, use of stop-smoking medications (including NRT) in the 
last year was recorded. Respondents were classified as having used NRT if they 
reported the use of any of the available six NRT products (patch, gum, lozenge, 
microtab, inhalator or nasal spray). Participants were asked whether, for the most 
recent use of NRT, they had used it for any of the following: to stop smoking, to 
reduce tobacco consumption, to cope with smoke-free environment or for other 
reasons. Due to a change in coding at wave 5, only those who had used NRT to stop 
smoking completely were also asked how they had obtained NRT (prescription, over 
the counter or off the shelf (OTC), from a friend). All NRT users were also asked 
whether they had continued to smoke while using NRT.  
 
Whilst the licensing change applied to only two NRT products (gum and inhaler), we 
have included all NRT in the analysis as a.) licensing for CDTS was restricted to the 
products of a particular manufacturer, which were not able to differentiate; b.) NRT 
other than gum and inhaler are likely to have been used for CDTS; and c.) including 
only gum and inhaler use dramatically reduces the sample and thus power to detect 
statistical differences where present. However, a sensitivity analysis that was 
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restricted to only gum and inhaler use was carried out to validate our findings, and 
this showed the same trends as reported in the analysis including all NRT products. 
 
Analyses 
Data were analysed using SPSS 16.0. Unadjusted preliminary analysis was carried 
out to identify potential confounders for adjusted analyses (see below). Differences in 
continuous or dichotomous variables between countries were assessed by chi square 
or t-test and differences between waves by generalised estimating equations (GEE) 
based on a logit (for dichotomous outcomes) or identity (for continuous outcomes) link 
function that used an exchangeable correlation matrix to model the interdependence 
between waves resulting from some participants being present in both waves. 
 
Adjusted analyses used GEE and included age, sex (in comparison countries), 
income (in UK), education and, where applicable, nicotine dependence (for ex-
smokers HSI values were imputed from the last available data point) as covariates to 
determine within-country changes and age and income to determine wave-country 
interactions. Where appropriate, adjusted cross-sectional analyses were carried out 
to further elucidate wave-dependent changes using logistic or linear regressions and 
included age, ethnicity, education and, where applicable, nicotine dependence as 
covariates. In order to control for unidentified, country-specific confounders, a 
categorical variable specifying each individual country was also included these 
adjusted between-country comparisons. 
 
RESULTS 
Preliminary unadjusted analysis 
Age increased from wave 3 to wave 5 in the UK and comparison countries (Table 1). 
This increase in age was more pronounced in comparison countries resulting in a 
country by wave interaction (Table 1). Overall, participants in the UK were older than 
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in comparison countries. In terms of sex distribution, there was a slight decrease in 
the proportion of men in comparison countries but not in the UK across waves, but no 
overall significant differences (Table 1). There were no changes in the ethnic 
distribution of participants between waves. Altogether, the UK was less ethnically 
diverse than comparison countries. The proportion of participants on a low income 
increased in the UK but not in comparison countries and there was a significant 
country by wave interaction (Table 1). The level of education also increased across 
waves in all countries but, overall, was lower in the UK than in comparison countries 
(Table 1). 
 
Table 1 about here 
 
There were no country by wave interactions on any of the smoking characteristics 
considered. Around 95% of the sample consisted of current smokers with no 
differences within or between countries (Table 1). Nicotine dependence (and in the 
UK also cigarette consumption) increased significantly from wave 3 to wave 5 in the 
UK and in comparison countries (Table 1) but there were no other within-country 
changes. Overall, smokers in the UK were less likely to intend or to have attempted to 
stop smoking and had carried out fewer quit attempts in the last year than current 
smokers in comparison countries (Table 1). There was a general trend towards 
increased NRT use across waves. Overall, more NRT was used in the UK than in 
comparison countries (see Table 1) 
 
Adjusted analyses 
1.) Impact of licence change on NRT use 
Confirming unadjusted analyses, NRT use in the general population increased across 
waves in both the UK (Wald χ2(1)=12.2, p<0.001) and in comparison countries (Wald 
χ2(1)=28.6, p<0.001) but no country by wave interaction was detected. However, 
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among quit attempters, NRT use significantly increased only in comparison countries 
(Wald χ2(1)=5.9, p=0.015) and not in the UK (Figure 1). Again, there was no country 
by wave interaction. Yet, smokers attempting to quit were more likely to use NRT in 
the UK than in any of the other countries at both wave 3 (OR range: 1.44-2.11; 95%CI 
range: 1.06-2.96) and wave 5 (OR range: 1.45-1.85; 95%CI range: 1.05-2.60) 
 
Figure 1 about here 
 
There was also an increase in the proportion of smokers attempting to quit who 
obtained NRT OTC in comparison countries (Wald χ2(1)=9.6, p=0.002) but not in the 
UK (Figure 1), which resulted in a significant country by wave interaction (Wald 
χ2(1)=5.80, p=0.016). Only at wave 5 (but not wave 3) were quit attempters in the UK 
less likely to obtain NRT OTC compared with quit attempters from any other country 
(OR range: 0.38-0.56; 95%CI range: 0.25-0.87). 
 
2.) Impact of license change on cutting down to stop smoking 
Among quit attempters, there was virtually no change in the prevalence of people 
using CDTS in the UK or in comparison countries and no country by wave interaction 
were observed (Figure 2). Whilst more participants in comparison countries attempted 
to quit by CDTS, there were no persistent significant differences between the UK and 
individual countries that were present at both waves. 
 
Figure 2 about here 
 
3.) Impact of license change on NRT use for cutting down to stop smoking 
A small increase in the use of NRT for CDTS was observed across waves in the UK 
and in comparison countries but this change was non-significant and no country by 
wave interaction was detected. Although more smokers in the UK used NRT for 
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CDTS (Figure 3), again there were no persistent differences between the UK and 
individual countries present at both waves.  
 
Figure 3 about here 
 
There were also no within-country changes across waves or a country by wave 
interaction in the proportion of quit attempters obtaining NRT OTC for CDTS (Figure 
3). 
4.) Impact of license change on quit attempts and concurrent smoking and NRT 
use among smokers not attempting to quit 
Around a third of participants had attempted to stop in the last year, making an 
average of two to three quit attempts (Table 1). There were no changes in the 
proportion or number of quit attempts made within the UK or comparison countries or 
a country by wave interaction. Overall, however, as in unadjusted analysis UK 
smokers were less likely to make a quit attempt than smokers from any other country 
at both wave 3 (OR range: 0.65-0.80; 95%CI range: 0.55-0.97) and wave 5 (OR 
range: 0.66-0.80; 95%CI range: 0.54-0.98) but there were no differences between the 
UK and other countries in the number of quit attempts smokers made at either wave. 
 
Concurrent smoking and NRT use among smokers not attempting to stop was not 
common. In the UK, there was an increase in NRT use among current smokers from 
wave 3 to 5 but no country by wave interaction was detected (Table 2). No data were 
available as to how NRT was obtained among smokers who were not attempting to 
quit. 
 
Table 2 about here 
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In a sub-analysis of this sample, there were no changes within the UK and 
comparison countries in the use of NRT simply to reduce consumption (as opposed to 
cut-down-to-stop) or to cope with temporary abstinence in adjusted analysis and no 
interactions were observed (Table 2). However, as this sample was small, the power 
to detect any significant changes was limited in this analysis. 
 
DISCUSSION 
These data suggest that the relaxation in the licensing laws of NRT in the UK to allow 
NRT use for CDTS had a very limited, if any, impact on NRT consumption and 
quitting behaviour, in the first year after the change was introduced. NRT use is more 
prevalent in the UK than in comparison countries and has generally become more 
popular across all countries that were evaluated, which may reflect both the 
increasing denormalisation of public smoking and NRT becoming more accessible. 
However, there was no change in the use of NRT by people attempting to quit in the 
UK relative to comparison countries. Moreover, although the relaxation of licensing 
was thought to impact mainly NRT obtained over the counter, there was no change in 
the use of NRT obtained OTC by smokers attempting to quit in the UK from 2004 to 
2007. Indeed, the use of NRT obtained OTC increased significantly in comparison 
countries relative to the UK. It appears that NRT use is more wide-spread in the UK 
but that it is more commonly purchased OTC in countries other than the UK, possibly 
because NRT is available relatively cheaply on prescription only in the UK and not in 
the comparison countries. 
 
The prevalence of smokers attempting to stop smoking using CDTS also did not 
change in the UK compared with other countries and was somewhat lower in the UK, 
which may reflect the great emphasis that has recently been placed on complete 
cessation in the UK [15]. In contrast, the use of NRT for cutting down to stop was 
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more common in the UK but there was no change in the use of NRT (irrespective how 
it was obtained) for cutting down to stop during the course of this study. 
 
The lack of positive findings may be the result of several factors. First, given that the 
survey covered the one-year period just after the introduction of new licensing laws, 
this timeframe may have been too immediate to pick up any changes in consumer 
behaviour. Second, the licensing change initially applied to only two products and not 
all brands [7]. Third, in contrast to an earlier study reporting an increase in NRT use 
after it was made available on prescription[12], the policy change considered here 
may have been too subtle to produce a notable effect. Fourth, a large number of 
smokers in these four countries reported using NRT to reduce cigarette consumption 
prior to 2005 [16]. For this reason, the already established use of NRT for reducing 
cigarette consumption in the UK before the licensing change may have contributed to 
a ceiling effect, thus reducing the potential to detect any substantial changes following 
the implementation of new licensing. Fifth, advertisement of the licensing change may 
have been insufficient to penetrate the market; approximately £1.5 million were spent 
on the advertising campaign for using NRT for CDTS (Johnson & Johnson, personal 
communication). The licensing change did not incorporate any specific promotion to 
educate the public or providers about how to conduct cut-down-to-stop or about its 
benefits. Rather, the packaging was modified and the licensing change advertised on 
TV, which may have been too minimal to change awareness, smoker behaviour or 
NRT utilisation. Indeed, it has been suggested that intensive outreach would be 
required before any benefit can be seen as most of the evidence supporting the use 
of NRT for CDTS has come from trials with considerable patient-investigator 
interaction.[17] 
 
One potential negative side-effect of more relaxed NRT licensing laws is that fewer 
people may attempt to stop smoking altogether and instead just use NRT while 
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continuing to smoke. When comparing the proportion of quit attempts in the UK and 
comparison countries, the change in licensing does not appear to have depressed the 
frequency or number of quit attempts across waves. There was some evidence that 
people continuing to smoke were more likely to use NRT in the UK after the licensing 
change but this increase was not significant relative to changes observed in 
comparison countries. 
 
This study had a number of limitations. Owing to its quasi-experimental design, it may 
be that other, potentially relevant, changes occurred in the UK or in the comparison 
countries that were not considered here and which could have affected results. Subtle 
trends such as growing ‘cessation fatigue’ following intensive campaigning may have 
confounded outcomes. Moreover, variations in the pricing of NRT across countries 
and the impending smoking ban in the UK may have contributed to results. Although 
this possibility cannot be excluded, we are not aware of any drastic changes in pricing 
over the period considered and the eventual introduction of a smoke ban in the UK 
was not announced until some time after data collection for the last wave had started. 
Indeed, the relaxation in NRT licensing laws in the UK was the only directly relevant 
legislative change implemented between waves. Furthermore, the inclusion of fairly 
comparable countries that – with the exception of NRT licensing - would have been 
exposed to similar, potentially relevant, changes across waves provides some 
measure of control. It can thus be reasonably assumed that differences in outcome 
measures in the UK relative to other countries can be attributed to the relaxation in 
NRT licensing in the UK that took place between waves.  
 
Another limitation of this study is its reliance on self-report to assess smoking status, 
quitting behaviour and NRT use, which may have resulted in some recall bias or 
misreporting. However, even if this is the case, there is no reason to believe that this 
should have differentially biased data from the UK and comparison countries. Lastly, 
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owing to low numbers we were not able to look statistically at changes in the use of 
particular forms of NRT. This would have been useful given that the licensing change 
initially targeted only two products. However, it is unclear that consumers would have 
differentiated between products in this respect. Indeed, the sensitivity analysis, 
restricted to these two forms revealed similar trends suggesting that potential 
changes in NRT use appear to have applied to the whole range of products. 
 
In conclusion, our data imply that over the time period covered by the two surveys, 
there was an overall increase in NRT use irrespective of whether people were from 
the UK or not. While there was no relative increase in the use of NRT for cutting down 
to stop, the results also suggest that making NRT available for gradual cessation has 
not had a detrimental effect on the proportion of quit attempts in the UK or led to an 
increase in the number of people attempting to stop gradually. Further research is 
required to substantiate these findings and evaluate their relevance for future public 
health policy. 
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Tables 
 
Table 1: Demographic and smoking characteristics of sample¥ 
 
UK  Comparison Countries” 
Country by wave 
interaction 
 Wave 3 
(N=1841) 
Wave 5 
(N=1713) 
Total 
(N=3554)
+
 
 
Wave 3 
(N=5545) 
Wave 5 
(N=5300) 
Total 
(N=10845)
$
 
Significance 
Demographic data         
       Mean (SD) Age   47.4  (14.0)   48.6  (14.4)*** 48.0  (16.3)    44.5  (14.0)
 
  46.8  (13.6)*** 45.6  (16.5)
‡
 P=0.005 
       Percent (n/N) Male   44.7  (
823
/1841)   43.0  (
737
/1713) 43.9  (
1560
/3554)    44.4  (
2460
/5545)   42.6  (
2258
/5300)* 43.5  (
4718
/10845) P=0.945 
       Percent (n/N) Majority 
       Culture 
  96.3  (
1770
/1838)   96.1  (
1643
/1710) 96.2  (
3413
/3548)    87.3  (
4825
/5530)   87.8  (
4650
/5294) 87.5  (
9475
/10824)
‡
 P=0.404 
      Percent (n/N) Low 
      Income 
  31.7  (
528
/1665)   36.7  (
575
/1565)** 34.2  (
1103
/3230)    33.2  (
1725
/5192)   32.5  (
1611
/4955) 32.9  (
2186
/10147) P=0.001 
      Percent (n/N) High 
      level of education 
  11.7  (
213
/1824)   13.3  (
226
/1697)** 12.5  (
439
/3521)    14.4 (
796
/5529)   16.5  (
871
/5291)*** 15.4  (
1097
/10820)
‡
 P=0.320 
Smoking characteristics         
      Percent (n/N) Current 
      Smokers 
  95.1  (
1750
/1841)   94.8  (
1624
/1713) 94.9  (
3374
/3554)    95.5  (
5296
/5545)   95.0  (
5035
/5300) 95.3  (
10331
/10845) P=0.734 
      Mean (SD) Cigarettes 
      per day
~
 
  17.2  (8.8)   16.9  (9.3)** 17.1  (10.2)
a
    18.0  (10.9)   18.3  (10.4) 18.2  (12.0)
b‡
 P=0.067 
      Mean (SD) HSI
~
     2.7  (1.4)     2.6  (1.4)**   2.7  (1.6)
c
      2.8  (1.5)     2.9  (1.5)**   2.8  (1.7)
d‡
 P=0.341 
      Percent (n/N) Intending  
      to quit
~
 
  61.8  (
1068
/1727)   61.1  (
972
/1591) 61.5  (
2040
/3318)    72.8  (
3797
/5216)   72.9  (
3604
/4944) 72.8  (
7401
/10160)
‡
 P=0.447 
      Percent (n/N) Attempting 
      to quit
 
in last year
#
 
  32.7  (
409
/1250)   32.0  (
357
/1115) 32.4  (
766
/2365)    38.9  (
1410
/3621)   36.9  (
1227
/3328) 37.9  (
2637
/6949)
‡
 P=0.678 
      Mean (SD) number of  
      quit attempts in last year
#
 
    2.3  (3.2)     2.0  (2.4)   2.2  (2.9)      3.1  (12.2)     3.5  (20.0)   3.3  (17.0)
‡
 P=0.413 
      Percent (n/N) Using  
      NRT
† 
in last year 
  17.7  (
325
/1841)   22.4  (
383
/1713)*** 19.9  (
708
/3554)    15.0  (
833
/5545)   19.0  (
1006
/5300)*** 17.0  (
1839
/10845)
‡
 P=0.752 
¥
Raw data are presented and comparisons based on generalised estimating equations (GEE); 
+
824 participants contributed to both waves; 
$
2483 participants contributed to both 
waves; “Australia, Canada and USA; 
~
Base is current smokers;
 #
Excludes participants not in previous survey;
 †
NRT-Nicotine Replacement Therapy 
 a
6 cases missing; 
b
8 cases 
missing; 
c
35 cases missing;
 d
102 cases missing;; 
‡
 Denotes significant differences between UK and comparison countries (p<.025); *Denotes significant difference between waves 
(p<.025) **Denotes significant difference between waves (p<.01); ***Denotes significant difference between waves (p<.001)
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Table 2: Prevalence of concurrent NRT use and smoking by wave and country¥ 
 
UK Comparison countries” 
Country by wave 
interaction 
Wave 3 Wave 5 Wave 3 Wave 5 Significance 
 Percent (n/N)  
Concurrent NRT use and 
smoking^ 
5.0 (
42
/841) 8.3 (
63
/758)* 4.8 (
107
/2211) 5.6 (
118
/2101) P=0.124 
    Only to reduce smoking
$
    21.4 (
9
/42)    34.9 (
22
/63)    13.1 (
14
/107)    18.6 (
22
/118) P=0.408 
    Only to cope with  
    temporary abstinence
$
 
   33.3 (
14
/42)    22.2 (
14
/63)    26.2 (
28
/107)    42.4 (
50
/118) P=0.410 
¥
Raw data are presented and comparisons based on generalised estimating equations (GEE) “Australia, Canada and USA; ^Base: 
Smokers not attempting to quit;
 $
Base: NRT users not attempting to stop; 
‡
 Denotes significant differences between countries 
(p<.025); *Denotes significant difference between waves (p<.025); **Denotes significant difference between waves (p<.01) 
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Figure Legend 
Figure 1: $Base for each wave (provided in each column): smokers/recent ex-smokers 
with reported quit attempt since previous survey; *OTC-Over the counter; ^CC-
Comparison Countries; Error bars represent 95% confidence interval of proportion 
 
Figure 2: +CDTS-Cut-down-to-stop; $Base for each wave (provided in each column): 
smokers/recent ex-smokers with reported quit attempt since previous survey; 
^Comparison Countries; º98 Cases missing; “19 Cases missing; Error bars represent 
95% confidence interval of proportion 
 
Figure 3: +CDTS-Cut-down-to-stop; $Base for each wave (provided in each column): 
smokers/recent ex-smokers who used CDTS;*OTC-Over the counter; ^Comparison 
Countries; Error bars represent 95% confidence interval of proportion 
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Figures 
Figure 1: Prevalence of recent NRT use among quit attempters by wave and country $ 
 
Figure 2: Prevalence of CDTS+ by wave and country$ 
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Figure 3: Prevalence of recent NRT use among quit attempters using CDTS+ by wave 
and country$ 
 
 
 
